<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <!-- Bootstrap CSS -->
        <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.2.0/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-gH2yIJqKdNHPEq0n4Mqa/HGKIhSkIHeL5AyhkYV8i59U5AR6csBvApHHNl/vI1Bx" crossorigin="anonymous">
    <!-- Custom CSS -->
        <link rel="stylesheet" href="css/style.css">
        <link rel="stylesheet" href="css/viewport-2048x1536.css"/>
        <style>
            .fixed-image{
                position: fixed;
                top: 0;
                left: 0;
                z-index: 9999999;
                opacity: 0.5;
                filter: invert(100%);
                width: 100vw;
                height: 100vh;
                /* margin-top: 1.4vw; */
            }
        </style>
</head>
<body>
    <!-- <img src="page-1.jpg" class="fixed-image"/>  -->
    <header class="page1_header fixedHeight">
        <div class="container_xxl  container-xxl-custom position-relative w-100">
            <strong>
                <p class="page1_box_1 text-uppercase h4">IN THE TREATMENT OF<br>MULTIPLE MYELOMA, NINLARO HAS</p>
            </strong>
            <h1 class="display-1 page1_box_2">DURABLE <span></span> STRENGTH</h1>

        </div>
        <div class="container-sub">
            <p class="page1_box_3 h4 pt-3 text-white text-center GothamBold">EXTENDED EFFICACY • MANAGEABLE TOLERABILITY • CONVENIENT ALL-ORAL, PI-BASED REGIMEN<sup>1,2</sup></p>
        </div>

    </header>
    <footer class="fixedFooter">
        <div class="footer_page1">
            <div class="container-fluid">
                <div class="footer_inner1">
                    <h5 class="GothamBold pb-2">INDICATION:</h5>
                    <p class="GothamMedium sub-h5">
                        Ixazomib (NINLARO) is indicated in combination with lenalidomide and dexamethasone for the treatment of adult <br> 
                        patients with multiple myeloma who have received at least one prior therapy.
                        <sup>1</sup> 
                    </p>
                </div>
            </div>
            <div class="footer_inner_nav1">
                <img class="gap-5" src="img/logo_orange.png" alt="">
                <ul>
                    <li>
                        <a href="page4.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                    </li>
                    <li>
                        <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" target="_blank" class="text-uppercase">pi</a>
                    </li>
                    <li>
                        <a href="page3.html" class="text-uppercase">ref</a>
                    </li>
                </ul>
                <p class="page_1_copy mb-0 ">C-APROM/PH/NINL/0015</p>
            </div>
        </div>
    </footer>
</body>
</html>